Question to the Department for Business, Energy and Industrial Strategy:

To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to the Answers of 19 January 2021 to Questions 137942 and 137941, if he will provide a breakdown of the £300 million invested in securing and scaling up UK manufacturing capacity by (a) type of capacity, (b) geographical location and (c) the date that investment was delivered.

The Government invested over £300 million in 2020 to secure and scale-up the UK’s manufacturing capabilities to respond to this pandemic, including:

- £127 million towards the Cell and Gene Therapy Catapult Braintree in Essex;

- £93 million to accelerate the completion and expanded role of the Vaccine Manufacturing Innovation Centre in Oxfordshire;

- £4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres;

- £8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire; and

- £65.5 million for the manufacture of the University of Oxford / AstraZeneca vaccine.

In addition to the above, we have also funded the fill and finish of vaccines through a contract with Wockhardt in Wrexham, North Wales, as well as the expansion of the Valneva factory in Livingston, Scotland. However, we are not able to give further details on these two developments owing to commercial confidentiality.